177 related articles for article (PubMed ID: 25281457)
1. Section IV: non-small cell lung cancer and malignant melanoma.
Fisher KE; Pillai RN; Kudchadkar RR; Rossi MR
Curr Probl Cancer; 2014; 38(5):180-98. PubMed ID: 25281457
[No Abstract] [Full Text] [Related]
2. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
[No Abstract] [Full Text] [Related]
3. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
[No Abstract] [Full Text] [Related]
4. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
5. Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Zer A; Leighl NB
J Clin Oncol; 2014 Jun; 32(18):1874-81. PubMed ID: 24841982
[No Abstract] [Full Text] [Related]
6. A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer.
Dai LJ; Wang C; Ding ZY
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1761-1766. PubMed ID: 30049184
[TBL] [Abstract][Full Text] [Related]
7. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
[TBL] [Abstract][Full Text] [Related]
8. Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?
Booton R; Blackhall F; Kerr K
Thorax; 2011 Apr; 66(4):273-5. PubMed ID: 21345972
[No Abstract] [Full Text] [Related]
9. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou SH
J Clin Pathol; 2013 Oct; 66(10):839-46. PubMed ID: 23661716
[TBL] [Abstract][Full Text] [Related]
10. [Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].
Maemondo M
Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1314-21. PubMed ID: 25151796
[No Abstract] [Full Text] [Related]
11. A survey of Japanese thoracic oncologists' perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer.
Hotta K; Kiura K; Tabata M; Takigawa N; Tanimoto M; Ueoka H
Chest; 2014 Dec; 146(6):e222-e225. PubMed ID: 25451370
[No Abstract] [Full Text] [Related]
12. Toward a Molecular Diagnosis in a Single Day for Patients With Advanced Non-small-cell Lung Cancer.
Lambros L; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e537-e538. PubMed ID: 29801704
[No Abstract] [Full Text] [Related]
13. [KRAS and bronchial adenocarcinoma. Between disappointments and hopes].
Guibert N; Ilie M; Léna H; Didier A; Hofman P; Mazieres J
Rev Mal Respir; 2016 Feb; 33(2):156-64. PubMed ID: 26520779
[TBL] [Abstract][Full Text] [Related]
14. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
15. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
16. [Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer].
Chen XX; Zhou CC
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):570-2. PubMed ID: 23157756
[No Abstract] [Full Text] [Related]
17. Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma.
Arfaoui A; Kriaa L; Znaidi N; Gritli S; Bouacha H; Zermani R; Rammeh S
J Immunoassay Immunochem; 2014; 35(3):256-68. PubMed ID: 24654822
[TBL] [Abstract][Full Text] [Related]
18. Glycosylated Alpha-1-acid glycoprotein 1 as a potential lung cancer serum biomarker.
Ayyub A; Saleem M; Fatima I; Tariq A; Hashmi N; Musharraf SG
Int J Biochem Cell Biol; 2016 Jan; 70():68-75. PubMed ID: 26563422
[TBL] [Abstract][Full Text] [Related]
19. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
[TBL] [Abstract][Full Text] [Related]
20. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
Reck M; Rabe KF
N Engl J Med; 2017 Aug; 377(9):849-861. PubMed ID: 28854088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
